LitCovid-sentences  

PMC:7441788 / 134-1685 JSONTXT 20 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T6 0-8 Sentence denotes ABSTRACT
T7 9-141 Sentence denotes Coronavirus Disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading worldwide.
T8 142-205 Sentence denotes Antiviral therapy is the most important treatment for COVID-19.
T9 206-353 Sentence denotes Among the drugs under investigation, anti-malarials, chloroquine (CQ) and hydroxychloroquine (HCQ), are being repurposed as treatment for COVID-19.
T10 354-531 Sentence denotes CQ/HCQ were shown to prevent receptor recognition by coronaviruses, inhibit endosome acidification, which interferes with membrane fusion, and exhibit immunomodulatory activity.
T11 532-618 Sentence denotes These multiple mechanisms may work together to exert a therapeutic effect on COVID-19.
T12 619-768 Sentence denotes A number of in vitro studies revealed inhibitory effects of CQ/HCQ on various coronaviruses, including SARS-CoV-2 although conflicting results exist.
T13 769-994 Sentence denotes Several clinical studies showed that CQ/HCQ alone or in combination with a macrolide may alleviate the clinical symptoms of COVID-19, promote viral conversion, and delay disease progression, with less serious adverse effects.
T14 995-1155 Sentence denotes However, recent studies indicated that the use of CQ/HCQ, alone or in combination with a macrolide, did not show any favorable effect on patients with COVID-19.
T15 1156-1259 Sentence denotes Adverse effects, including prolonged QT interval after taking CQ/HCQ, may develop in COVID-19 patients.
T16 1260-1551 Sentence denotes Therefore, current data are not sufficient enough to support the use of CQ/HCQ as therapies for COVID-19 and increasing caution should be taken about the application of CQ/HCQ in COVID-19 before conclusive findings are obtained by well-designed, multi-center, randomized, controlled studies.